{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:42:45Z","timestamp":1791294165566,"version":"4.1.0"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.clim.2016.07.006","type":"journal-article","created":{"date-parts":[[2016,7,17]],"date-time":"2016-07-17T19:45:38Z","timestamp":1468784738000},"page":"105-110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Metastatic melanoma and immunotherapy"],"prefix":"10.1016","volume":"172","author":[{"given":"Benjamin","family":"Herzberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2016.07.006_bb0005","series-title":"Cancer Facts & Figures 2016","author":"American Cancer Society","year":"2016"},{"issue":"4","key":"10.1016\/j.clim.2016.07.006_bb0010","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.clim.2016.07.006_bb0015","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nrclinonc.2013.208","article-title":"Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer","volume":"11","author":"Drake","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.clim.2016.07.006_bb0020","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nrc1782","article-title":"Paradoxical roles of the immune system during cancer development","volume":"6","author":"de Visser","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"17","key":"10.1016\/j.clim.2016.07.006_bb0025","doi-asserted-by":"crossref","first-page":"6719","DOI":"10.1073\/pnas.86.17.6719","article-title":"Selective changes in expression of HLA class I polymorphic determinants in human solid tumors","volume":"86","author":"Natali","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.clim.2016.07.006_bb0030","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1073\/pnas.89.8.3488","article-title":"Altered binding of regulatory factors to HLA class I enhancer sequence in human tumor cell lines lacking class I antigen expression","volume":"89","author":"Blanchet","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.clim.2016.07.006_bb0035","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.4049\/jimmunol.137.9.3036","article-title":"Stepwise immunologic selection of antigenic variants during tumor growth","volume":"137","author":"Urban","year":"1986","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.clim.2016.07.006_bb0040","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10555-006-9002-6","article-title":"Effect of tumor-derived cytokines and growth factors on differentiation and immune suppressive features of myeloid cells in cancer","volume":"25","author":"Kusmartsev","year":"2006","journal-title":"Cancer Metastasis Rev."},{"issue":"5588","key":"10.1016\/j.clim.2016.07.006_bb0045","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1126\/science.1073514","article-title":"Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase","volume":"297","author":"Munn","year":"2002","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.clim.2016.07.006_bb0050","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2006-02-002774","article-title":"Regulatory T cells in cancer","volume":"108","author":"Beyer","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clim.2016.07.006_bb0055","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/00000441-189305000-00001","article-title":"The treatment of malignant tumors by repeated inoculations of erysipelas with a report of ten original cases","volume":"105","author":"Coley","year":"1893","journal-title":"Am. J. Med. Sci."},{"issue":"3","key":"10.1016\/j.clim.2016.07.006_bb0060","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/00000658-195609000-00007","article-title":"Spontaneous regression of cancer: preliminary report","volume":"144","author":"Cole","year":"1956","journal-title":"Ann. Surg."},{"issue":"8231","key":"10.1016\/j.clim.2016.07.006_bb0065","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0140-6736(81)92359-X","article-title":"Malignant melanoma in renal-transplant recipients","volume":"1","author":"Greene","year":"1981","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.clim.2016.07.006_bb0070","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.clim.2016.07.006_bb0075","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.clim.2016.07.006_bb0080","first-page":"S55","article-title":"Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma","volume":"6","author":"Fisher","year":"2000","journal-title":"Cancer J. Sci. Am."},{"issue":"Suppl 1","key":"10.1016\/j.clim.2016.07.006_bb0085","first-page":"S11","article-title":"High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update","volume":"6","author":"Atkins","year":"2000","journal-title":"Cancer J. Sci. Am."},{"issue":"1","key":"10.1016\/j.clim.2016.07.006_bb0090","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/00002371-199207000-00009","article-title":"Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell lung cancer","volume":"12","author":"Jansen","year":"1992","journal-title":"J. Immunother."},{"issue":"1","key":"10.1016\/j.clim.2016.07.006_bb0095","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00000421-199502000-00010","article-title":"Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer","volume":"18","author":"Schiller","year":"1995","journal-title":"Am. J. Clin. Oncol."},{"issue":"5038","key":"10.1016\/j.clim.2016.07.006_bb0100","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1840703","article-title":"A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma","volume":"254","author":"van der Bruggen","year":"1991","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.clim.2016.07.006_bb0105","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.4049\/jimmunol.174.5.3080","article-title":"MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma","volume":"174","author":"Chianese-Bullock","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2016.07.006_bb0110","doi-asserted-by":"crossref","first-page":"h988","DOI":"10.1136\/bmj.h988","article-title":"Cancer vaccines","volume":"350","author":"Butterfield","year":"2015","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.clim.2016.07.006_bb0115","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1200\/JCO.2003.06.041","article-title":"Current developments in cancer vaccines and cellular immunotherapy","volume":"21","author":"Ribas","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.clim.2016.07.006_bb0120","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrclinonc.2014.111","article-title":"Therapeutic vaccines for cancer: an overview of clinical trials","volume":"11","author":"Melero","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.clim.2016.07.006_bb0125","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/jcb.21473","article-title":"Melanoma cancer vaccines and anti-tumor T cell responses","volume":"102","author":"Vujanovic","year":"2007","journal-title":"J. Cell. Biochem."},{"issue":"2","key":"10.1016\/j.clim.2016.07.006_bb0130","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4049\/jimmunol.154.2.730","article-title":"Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen","volume":"154","author":"Hoon","year":"1995","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.clim.2016.07.006_bb0135","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/ijc.21264","article-title":"Phase 1\/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma","volume":"117","author":"Kruit","year":"2005","journal-title":"Int. J. Cancer"},{"issue":"4","key":"10.1016\/j.clim.2016.07.006_bb0140","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nri3191","article-title":"Adoptive immunotherapy for cancer: harnessing the T cell response","volume":"12","author":"Restifo","year":"2012","journal-title":"Nat. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.clim.2016.07.006_bb0145","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJM199008303230904","article-title":"Gene transfer into humans\u2013immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction","volume":"323","author":"Rosenberg","year":"1990","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.clim.2016.07.006_bb0150","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N. Engl. J. Med."},{"issue":"5594","key":"10.1016\/j.clim.2016.07.006_bb0155","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.clim.2016.07.006_bb0160","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.clim.2016.07.006_bb0165","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrc3565","article-title":"Gene-engineered T cells for cancer therapy","volume":"13","author":"Kershaw","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.clim.2016.07.006_bb0170","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol. Rev."},{"issue":"6501","key":"10.1016\/j.clim.2016.07.006_bb0175","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/372100a0","article-title":"T-cell apoptosis detected in situ during positive and negative selection in the thymus","volume":"372","author":"Surh","year":"1994","journal-title":"Nature"},{"issue":"6127","key":"10.1016\/j.clim.2016.07.006_bb0180","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/328267a0","article-title":"A new member of the immunoglobulin superfamily\u2013CTLA-4","volume":"328","author":"Brunet","year":"1987","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.clim.2016.07.006_bb0185","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1084\/jem.174.3.561","article-title":"CTLA-4 is a second receptor for the B cell activation antigen B7","volume":"174","author":"Linsley","year":"1991","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.clim.2016.07.006_bb0190","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","article-title":"CTLA-4 can function as a negative regulator of T cell activation","volume":"1","author":"Walunas","year":"1994","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.clim.2016.07.006_bb0195","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1084\/jem.183.6.2541","article-title":"CTLA-4 ligation blocks CD28-dependent T cell activation","volume":"183","author":"Walunas","year":"1996","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.clim.2016.07.006_bb0200","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.clim.2016.07.006_bb0205","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"issue":"5238","key":"10.1016\/j.clim.2016.07.006_bb0210","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.270.5238.985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.clim.2016.07.006_bb0215","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-03-3259","article-title":"PD-L1\/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells","volume":"64","author":"Blank","year":"2004","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.clim.2016.07.006_bb0220","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.clim.2016.07.006_bb0225","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J."},{"key":"10.1016\/j.clim.2016.07.006_bb0230","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.clim.2016.07.006_bb0235","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2051-1426-2-3","article-title":"Mechanism of tumor rejection with doublets of CTLA-4, PD-1\/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment","volume":"2","author":"Spranger","year":"2014","journal-title":"J. Immunother. Cancer"},{"issue":"7077","key":"10.1016\/j.clim.2016.07.006_bb0240","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.clim.2016.07.006_bb0245","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.clim.2016.07.006_bb0250","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1182\/blood-2008-12-195792","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","volume":"114","author":"Ahmadzadeh","year":"2009","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clim.2016.07.006_bb0255","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1074-7613(00)80089-8","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","journal-title":"Immunity"},{"issue":"5502","key":"10.1016\/j.clim.2016.07.006_bb0260","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.clim.2016.07.006_bb0265","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","article-title":"Role of LAG-3 in regulatory T cells","volume":"21","author":"Huang","year":"2004","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.clim.2016.07.006_bb0270","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res."},{"issue":"5256","key":"10.1016\/j.clim.2016.07.006_bb0275","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"issue":"26","key":"10.1016\/j.clim.2016.07.006_bb0280","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.clim.2016.07.006_bb0285","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.clim.2016.07.006_bb0290","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.clim.2016.07.006_bb0295","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1158\/1078-0432.CCR-11-1823","article-title":"CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma","volume":"18","author":"Prieto","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.clim.2016.07.006_bb0300","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1093\/annonc\/mdt161","article-title":"Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials","volume":"24","author":"Wolchok","year":"2013","journal-title":"Ann. Oncol."},{"issue":"17","key":"10.1016\/j.clim.2016.07.006_bb0305","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.2014.59.5041","article-title":"Gauging the long-term benefits of ipilimumab in melanoma","volume":"33","author":"Ribas","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.clim.2016.07.006_bb0310","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.clim.2016.07.006_bb0315","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.clim.2016.07.006_bb0320","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1002\/cncr.28620","article-title":"Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors","volume":"120","author":"Ackerman","year":"2014","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.clim.2016.07.006_bb0325","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/jama.2016.4012","article-title":"PD-1 blockade in melanoma: a promising start, but a long way to go","volume":"315","author":"Bhatia","year":"2016","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.clim.2016.07.006_bb0330","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.clim.2016.07.006_bb0335","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMc1509660","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.clim.2016.07.006_bb0340","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.clim.2016.07.006_bb0345","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nrclinonc.2013.245","article-title":"Mitigating the toxic effects of anticancer immunotherapy","volume":"11","author":"Gangadhar","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.clim.2016.07.006_bb0350","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.clim.2016.07.006_bb0355","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.clim.2016.07.006_bb0360","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7528","key":"10.1016\/j.clim.2016.07.006_bb0365","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.clim.2016.07.006_bb0370","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1158\/1078-0432.CCR-15-0244","article-title":"Differential expression of immune-regulatory genes associated with PD-L1 display in melanoma: implications for PD-1 pathway blockade","volume":"21","author":"Taube","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2016.07.006_bb0375","doi-asserted-by":"crossref","first-page":"10582","DOI":"10.1038\/ncomms10582","article-title":"Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1\/PD-L1 therapy","volume":"7","author":"Johnson","year":"2016","journal-title":"Nat. Commun."},{"issue":"7528","key":"10.1016\/j.clim.2016.07.006_bb0380","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.clim.2016.07.006_bb0385","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1200\/JCO.2011.38.4032","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB\/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study","volume":"30","author":"Lynch","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.clim.2016.07.006_bb0390","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/annonc\/mds213","article-title":"Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial","volume":"24","author":"Reck","year":"2013","journal-title":"Ann. Oncol."},{"issue":"26","key":"10.1016\/j.clim.2016.07.006_bb0395","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.clim.2016.07.006_bb0400","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.clim.2016.07.006_bb0405","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2016.07.006_bb0410","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer","author":"Rizvi","year":"2015","journal-title":"Science"},{"issue":"6257","key":"10.1016\/j.clim.2016.07.006_bb0415","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.clim.2016.07.006_bb0420","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"7528","key":"10.1016\/j.clim.2016.07.006_bb0425","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nature14001","article-title":"Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.clim.2016.07.006_bb0430","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrg3945","article-title":"Clinical genetics. Sequencing for tailored melanoma immunotherapy","volume":"16","author":"Jones","year":"2015","journal-title":"Nat. Rev. Genet."},{"issue":"1","key":"10.1016\/j.clim.2016.07.006_bb0435","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol."},{"issue":"11","key":"10.1016\/j.clim.2016.07.006_bb0440","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"Sanlorenzo","year":"2015","journal-title":"JAMA Dermatol."},{"issue":"2","key":"10.1016\/j.clim.2016.07.006_bb0445","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nri724","article-title":"Epitope spreading in immune-mediated diseases: implications for immunotherapy","volume":"2","author":"Vanderlugt","year":"2002","journal-title":"Nat. Rev. Immunol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661616301814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661616301814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T07:10:44Z","timestamp":1692429044000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661616301814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":89,"alternative-id":["S1521661616301814"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2016.07.006","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metastatic melanoma and immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2016.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}